It’s a lazy “paywall”.

Genetically engineering tobacco plants could enable a more sustainable production method for psychedelic drugs, which are increasingly in demand for research and medical uses.

With the addition of nine genes, the plants were able to produce psilocin and psilocybin, usually found in mushrooms; DMT from various plants; and bufotenin and 5-methoxy-DMT, compounds secreted by the Colorado river toad (Incilius alvarius).

a) is it BS

The tobacco plant is a model plant, the go-to for genetic engineering experiments. So often when scientists want to test creating a bio-factory, they will try to modify a tobacco plant.

I am knowledgeable in ethnobotany and psychedelics and I cannot see what this might produce other than nausea and delirium.

The idea is not to smoke the resulting tobacco plant with some funky mix of psychedelics. But to extract and purify the compounds from the bio-factory. Resulting in a better production chain than however the compounds are typically made today.

it’s not about selling it as a product. it’s about determining what molecular pathways are interchangeable between plants, fungus and animals.

Tobacco plant altered to produce five psychedelic drugs

Genetically engineering tobacco plants could enable a more sustainable production method for psychedelic drugs, which are increasingly in demand for research and medical uses

Scientists have engineered tobacco plants to produce five powerful psychedelic compounds normally found in other plants, fungi and animals in a single crop. They argue that using plants to manufacture the drugs would be simpler and more sustainable than existing processes, making research into therapeutic uses and production of future medicines easier.

Asaph Aharoni at the Weizmann Institute of Science in Israel and his colleagues modified Nicotiana benthamiana plants using a technique called agroinfiltration, which involves using a bacterium to introduce genes from other organisms into a plant. The modified plant then makes the proteins encoded by those genes, but the DNA isn’t incorporated into the plant’s genome, so the effect is short-lived.

With the addition of nine genes, the plants were able to produce psilocin and psilocybin, usually found in mushrooms; DMT from various plants; and bufotenin and 5-methoxy-DMT, compounds secreted by the Colorado river toad (Incilius alvarius).

Plants could easily be altered permanently with changes that become inheritable, but doing so could be problematic, given that the compounds produced are commonly used as recreational drugs, says Aharoni. “It’s a little bit tricky if we have it inherited, and then people will ask for seeds,” he says. “We can do it also in tomato, potato, corn.”

The medical uses of psychedelic compounds are becoming more popular and better understood, says Aharoni, but harvesting them from natural sources risks populations threatened by habitat loss and overexploitation. The drugs are chemically synthesised for use in research, but producing them in tobacco plants, which are easily cultivated in greenhouses, would be much simpler.

The idea of growing drugs through pharmaceutical farming, or “pharming”, certainly isn’t new. Plant-produced protein drugs have been approved in the US since 2012, and as far back as 2002, maize has been modified to produce a pharmaceutical protein. Another research team used tobacco plants in 2022 to synthesise cocaine, discovering that it could produce about 400 nanograms of cocaine per milligram of dried leaf – about a 25th of the level in a coca plant.

Rupert Fray at the University of Nottingham, UK, says around 25 per cent of prescription drugs are derived wholly or partially from plants, and there are massive opportunities to create “green factories” that can grow new compounds in greenhouses.

“If you want to understand something, you’ve got to be able to build something, so showing that you can make it in tobacco plants is useful,” says Fray. “As a technical accomplishment, to show that you understand the pathways and can do it, I think it has value.”

https://www.science.org/doi/10.1126/sciadv.aeb3034

Berman et al., Sci. Adv. 12, eaeb3034 (2026) 1 April 2026

S c i e n c e A d v

A

n c e

S

| R e

S

e

A R

c h A

R

t i c l e

1 of 18

P L A N T S C I E N C E S

Complete biosynthesis of psychedelic tryptamines from

three kingdoms in plants

Paula Berman1,2

*†, Janka Höfer 1

†, Herschel Mehlman1

, Efrat Almekias-Siegl1

, Olga Khersonsky 3

,

Younghui Dong 4

‡, Uwe Heinig4

, Liron Sulimani5

, Let Kho Hao1,2

, Shahar Cohen2

, Yoav Peleg4

,

Sagit Meir1

, Ilana Rogachev 1

, David Meiri5

, Sarel J. Fleishman3

, Asaph Aharoni1

*

Psychedelic indolethylamines with therapeutic potential are naturally produced in plants, fungi, and animals.

Here, we elucidated the complete N,N-dimethyltryptamine (DMT) biosynthetic pathway in hallucinogenic plant

species traditionally used in shamanic rituals for spiritual healing. Leveraging the similarities in their chemical

structures, we reconstructed in one plant assay the full biosynthetic pathways of five renowned natural psyche-

delics; psilocin and psilocybin found in mushrooms, DMT from plants, and bufotenin and 5-methoxy-DMT secret-

ed by the Sonoran Desert toad. We further engineered halogenated analogs of these molecules, which do not

naturally occur in plants and exhibit prospective therapeutic potential for psychiatric conditions. Blending cata-

lytic functions across the tree of life, coupled with metabolic engineering guided by rational protein design of

mutant enzymes, enabled substantially more efficient in planta production of the indolethylamine components.

This work establishes a versatile platform for concurrent biosynthesis and diversification of psychoactive indole-

thylamines, paving the way for their production in plants.

INTRODUCTION

For thousands of years, psychedelic substances have been used by

indigenous cultures as entheogens in rituals intended to induce al-

tered states of consciousness for spiritual and therapeutic purposes.

Psilocybin-containing mushrooms were central to ancient Aztec

ceremonies (1), while N,N-dimethyltryptamine (DMT), the pri-

mary psychoactive component of ayahuasca, has long been used

in traditional Amazonian rituals. This ceremonial brew combines

Psychotria viridis (a natural source of DMT) with Banisteriopsis caapi,

which provides β-carboline monoamine oxidase (MAO) inhibi-

tors that render DMT orally active (1, 2). Similarly, 5-methoxy-N,N-

dimethyltryptamine (5-MeO-DMT), found in the secretion of

the Sonoran Desert toad (Incilius alvarius) and in several plant spe-

cies, is thought to have been used ceremonially by indigenous

groups in northern Mexico (3). 5-MeO-DMT has been described

as the most potent DMT analog, being about 4- to 10-fold more po-

tent than DMT in humans and is known to induce psychedelic ex-

periences that are distinct from those of DMT (4). Knowledge of

the traditional use of these molecules has fueled contemporary

therapeutic interest in psychedelics as treatments for neuropsychiat-

ric conditions.

Recent studies have shown that classical indolethylamine psy-

chedelics promote neuroplasticity and modulate serotonergic cir-

cuits, primarily through 5-HT 2A receptor activation (5–7). These

compounds have demonstrated therapeutic potential for depression,

anxiety, posttraumatic stress disorder, and addiction (5–8), with psi-

locybin receiving Food and Drug Administration Breakthrough

Therapy designation for major depressive disorder in 2019 (6, 7).

Although widely considered hallucinogenic, psilocybin itself func-

tions as a prodrug, undergoing enzymatic dephosphorylation in the

digestive tract and liver to produce psilocin, the active compound

responsible for its psychoactive effects. DMT is produced by a broad

range of plant species and, in low abundance, by certain animals (2).

When administered via smoking or intravenous injection, it pro-

duces rapid and intense psychoactive effects that typically peak with-

in 5 min and subside within 30 min, due to rapid metabolism by

MAO enzymes in the liver. Coadministration with MAO inhibitors

can extend the half-life of DMT in vivo (2). The traditional use of

ayahuasca exemplifies how combining compounds from different

sources can enable oral activity; however, such combinations require

carefully balanced dosing to mitigate adverse effects associated with

MAO inhibition (9).

The expanding clinical interest in psychedelics as therapeutics

has sparked the need for scalable and versatile production platforms

and structural diversification (10, 11). Traditionally, the supply of

psychedelics relies on natural producers, mainly plants, fungi, and

the Sonoran Desert toad. Harvesting these organisms for their psy-

choactive compounds raises ecological and ethical concerns, being

increasingly threatened by habitat loss and overexploitation (12).

While synthetic routes for these compounds are available and, in

some cases, relatively straightforward, they still require compound-

specific reactants, can lead to unwanted intermediates and prod-

ucts, and require several processing steps (2, 13, 14). Biocatalys